SPRI | Translational Research Methods In Diabetes, Obesity, And Nonalcoholic Fatty Liver Disease, 2nd Edition (2019 EN)

Discussion in 'Medicine' started by Kanka, Aug 1, 2020.

  1. Kanka

    Kanka Well-Known Member Loyal User

    Messages:
    11,987
    Likes Received:
    308
    Trophy Points:
    83
    [​IMG]

    Author: Andrew J. Krentz (Editor), Christian Weyer (Editor), Marcus Hompesch (Editor)
    Full Title: Translational Research Methods In Diabetes, Obesity, And Nonalcoholic Fatty Liver Disease: A Focus On Early Phase Clinical Drug Development, 2nd Edition
    Publisher: Springer; 2nd ed. 2019 edition (April 2, 2019)
    Year: 2019
    ISBN-13: 9783030117481 (978-3-030-11748-1), 9783030117474 (978-3-030-11747-4)
    ISBN-10: 3030117480, 3030117472
    Pages: 556
    Language: English
    Genre: Medicine: Internal Medicine
    File type: EPUB (True), PDF (True)
    Quality: 10/10
    Price: 83.19 €


    This book aims to aid the selection of the most appropriate methods for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and related cardiometabolic disorders.

    Clinical research methods to assess the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycemic clamp technique, have become well-established in proof-of-mechanism studies. However, selection of the most appropriate techniques is by no means straightforward. Moreover, the application of such methods must conform to the regulatory requirements for new drugs.

    This book discusses the need for new pharmacotherapies for diabetes, obesity and NAFLD and the molecular targets of drugs currently in development. Emerging technologies including functional imaging, circulating biomarkers and omics are considered together with practical and ethical issues pertaining to early phase clinical trials in subjects with cardiometabolic disorders.

    Translational Research Methods in Diabetes, Obesity, and Non-Alcoholic Fatty Liver Disease is of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.

    -------------
     

Share This Page